Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLoans and Notes ReceivablesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Lensar (LNSR) Long-Term Debt Issuances (2019 - 2020)

Lensar (LNSR) reported Long-Term Debt Issuances of $2.0 million for Q3 2020, down 72.97% on a QoQ basis from $7.4 million in Q2 2020.

Lensar (LNSR) has 2 years of Long-Term Debt Issuances data on file, last reported at $2.0 million in Q3 2020.

  • Quarterly Long-Term Debt Issuances changed N/A year-over-year to $2.0 million in Q3 2020, while the trailing twelve-month figure through Dec 2020 was $12.4 million (changed N/A YoY) and the FY2020 annual result came in at $12.4 million, down 6.24% from the prior year.
  • Long-Term Debt Issuances fell to $2.0 million in Q3 2020 per LNSR's latest filing, from $7.4 million in the prior quarter.
  • Across five years, Long-Term Debt Issuances topped out at $9.0 million in Q4 2019 and bottomed at $2.0 million in Q3 2020.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Issuances (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 19.86 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn 11.71 Mn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn 1.15 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -
10 Lensar 69.32 Mn 69.61 Mn 6.38 Mn -

Historic Data

Download Data 🔒
DateValue
Sep 30, 2020 2.00 Mn
Sep 30, 2020 2.00 Mn
Jun 30, 2020 7.40 Mn
Jun 30, 2020 7.40 Mn
Mar 31, 2020 3.00 Mn
Mar 31, 2020 3.00 Mn
Dec 31, 2019 9.00 Mn
Dec 31, 2019 9.00 Mn